2024-04-04 03:48:45 ET
Summary
- Butterfly Network is commercializing an AI-powered handheld ultrasound device but only expects modest growth in 2024.
- Recurring losses and a large cash flow bleed are expected to continue through 2025.
- We expect shares to remain under pressure until BFLY proves its commercialization strategy is sustainable.
Butterfly Network, Inc. ( BFLY ) has launched the FDA-cleared "Butterfly iQ3" as an AI-powered handheld ultrasound device seen as a cost-effective alternative to traditional body-scanning equipment....
Read the full article on Seeking Alpha
For further details see:
Butterfly Network Stock: Weak Growth Adds To Downside Risk